A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

被引：6
|
作者：
Assouline, Sarit [1 ]
Michaelis, Laura C. [2 ]
Othus, Megan [3 ]
Hay, Annette E. [4 ]
Walter, Roland B. [5 ]
Jacoby, Meagan A. [6 ]
Schroeder, Mark A. [6 ]
Uy, Geoffrey L. [6 ]
Law, Lisa Y. [7 ]
Cheema, Faisal [8 ]
Sweet, Kendra L. [9 ]
Asch, Adam S. [10 ]
Liu, Jijun [11 ]
Moseley, Anna B. [2 ]
Maher, Tracy [12 ]
Kingsbury, Laura L. [12 ]
Fang, Min [5 ]
Radich, Jerald [5 ]
Little, Richard F. [13 ]
Erba, Harry P. [14 ]
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[2] Med Coll Wisconsin, Milwaukee, WI USA
[3] SWOG Stat & Data Management Ctr, Seattle, WA USA
[4] Queens Univ, Kingston, ON, Canada
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Kaiser Permanente NCAL, Roseville, CA USA
[8] Kaiser Permanente, Santa Clara, CA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[10] Univ Oklahoma HSC, Oklahoma City, OK USA
[11] Illinois Canc Care Heartland NCORP, Peoria, IL USA
[12] SWOG Data Operat Ctr, Canc Res & Biostat, Seattle, WA USA
[13] Natl Canc Inst, Canc Therapy & Evaluat Program CTEP, Bethesda, MD USA
[14] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 02期
基金：
美国国家卫生研究院;
关键词：
CONVENTIONAL-CARE-REGIMENS; THERAPY;
D O I：
10.1080/10428194.2022.2148212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：473 / 477
页数：5
相关论文
共 50 条
  • [41] RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
    Dombret, H.
    Seymour, J. F.
    Butrym, A.
    Wierzbowska, A.
    Selleslag, D.
    Jang, J. H.
    Kumar, R.
    Cavenagh, J.
    Schuh, A.
    Candoni, A.
    Recher, C.
    Sandhu, I.
    Bernal, T.
    Al-Ali, H. K.
    Martinelli, G.
    Stone, R. M.
    Minden, M. D.
    McIntyre, H.
    Songer, S.
    Lucy, L.
    Beach, C.
    Doehner, H.
    HAEMATOLOGICA, 2014, 99 : 788 - 789
  • [42] Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    Garcia-Manero, G.
    Yang, A. S.
    Klimek, V.
    Luger, S.
    Newsome, W. M.
    Berman, N.
    Patterson, T.
    Maroun, C.
    Li, Z.
    Ward, R.
    Martell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
    Garcia-Manero, Guillermo
    Yang, Allen S.
    Giles, Francis
    Faderl, Stefan
    Ravandi, Farhad
    Cortes, Jorge
    Newsome, Willie M.
    Issa, Jean-Pierre
    Patterson, Tracy-Ann
    Dubay, Marja
    Li, Zuomei
    Kantarjian, Hagop
    Martell, Robert E.
    BLOOD, 2006, 108 (11) : 552A - 553A
  • [44] A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).
    Garcia-Manero, Guillermo
    Fong, Chun Yew
    Venditti, Adriano
    Mappa, Silvia
    Spezia, Riccardo
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Results of a Phase 2, Open-Label Study of Idarubicin, Cytarabine, and Nivolumab in Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 9 - 11
  • [46] A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
    Silverman, L. R.
    Verma, A.
    Odchimar-Reissig, R.
    Cozza, A.
    Najfeld, V.
    Licht, J. D.
    Zwiebel, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study
    DiNardo, Courtney D.
    Schuh, Andre C.
    Stein, Eytan M.
    Fernandez, Pau Montesinos
    Wei, Andrew
    De Botton, Stephane
    Zeidan, Amer M.
    Fathi, Amir T.
    Quek, Lynn
    Kantarjian, Hagop M.
    Frattini, Mark G.
    Lersch, Frederik
    Gong, Jing
    Franovic, Aleksandra
    MacBeth, Kyle
    Vyas, Paresh
    Dohner, Hartmut
    BLOOD, 2019, 134
  • [48] Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
    Thierry Guillaume
    Florent Malard
    Leonardo Magro
    Myriam Labopin
    Reza Tabrizi
    Cécile Borel
    Patrice Chevallier
    Stéphane Vigouroux
    Pierre Peterlin
    Alice Garnier
    Marie-Thérèse Rubio
    Anne Huynh
    Noël Milpied
    Philippe Moreau
    Béatrice Gaugler
    Ibrahim Yakoub-Agha
    Mohamad Mohty
    Bone Marrow Transplantation, 2019, 54 : 1815 - 1826
  • [49] Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
    Guillaume, Thierry
    Malard, Florent
    Magro, Leonardo
    Labopin, Myriam
    Tabrizi, Reza
    Borel, Cecile
    Chevallier, Patrice
    Vigouroux, Stephane
    Peterlin, Pierre
    Garnier, Alice
    Rubio, Marie-Therese
    Huynh, Anne
    Milpied, Noel
    Moreau, Philippe
    Gaugler, Beatrice
    Yakoub-Agha, Ibrahim
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2019, 54 (11) : 1815 - 1826
  • [50] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 903 - 903
12345